Oxford Pharmascience, a speciality pharmaceutical company, has successfully completed the formulation development for its Safestat drugs, Atorvastatin and Simvastatin.
The developments continue the company's Safestat programme, which aims to re-formulate the widely used molecules of atorvastatin and simvastatin into doses up to four times lower than the original dose, but with the same lipid-lowering properties as the original higher dose.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
How does the Lifetime ISA work? Key LISA rulesWhat is a Lifetime ISA (LISA) and how much could the government bonus boost your savings by? We look at the perks and the pitfalls.
-
AJ Bell: a fine British fintech going cheapOpinion Don’t overlook investment platform AJ Bell, a significantly undervalued British business with an excellent financial base
